Venkatram Rajaram, MD
Cardiovascular Disease · Edmond, OKNPI 1154359768
Payments from drug & device makers
Across 434 payments — averaging $46.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$8K
- Abbott$4K
- Medtronic$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Johnson & Johnson$934
- Boston Scientific$619
- plus $3K from 32 others
What the payments were for
- Travel & lodging$3,44217%
- Food & beverage$9,19946%
- Education$720%
- Other$7,38337%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $7,546 |
| Abbott | 106 | $3,950 |
| Medtronic(2 entities) | 59 | $3,219 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 77 | $1,056 |
| Johnson & Johnson | 47 | $934 |
| Boston Scientific | 11 | $619 |
| AstraZeneca | 13 | $380 |
| Pfizer | 25 | $310 |
| Abiomed | 6 | $212 |
| Bard Peripheral Vascular, Inc. | 5 | $188 |
| Boehringer Ingelheim | 11 | $178 |
| Novartis | 8 | $166 |
| Esperion Therapeutics, Inc. | 8 | $143 |
| Chiesi USA, Inc. | 7 | $135 |
| Cardiovascular Systems Inc. | 1 | $98 |
| Merck | 6 | $95 |
| Impulse Dynamics (USA) Inc. | 4 | $90 |
| Asahi Intecc USA, Inc. | 2 | $86 |
| E.r. Squibb & Sons, L.L.C. | 3 | $79 |
| Inari Medical, Inc. | 4 | $78 |
| Novo Nordisk | 3 | $63 |
| W. L. Gore & Associates, Inc. | 2 | $59 |
| Cook Medical LLC | 3 | $44 |
| Kestra Medical Technology Services, Inc. | 2 | $43 |
| BD | 1 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $33 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Amgen | 2 | $31 |
| Tactile Systems Technology Inc | 1 | $24 |
| Cvrx, Inc. | 1 | $21 |
| Smith+Nephew | 1 | $18 |
| GSK | 1 | $18 |
| Cardiva Medical, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $17 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Edwards Lifesciences | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$7,530
- AVEIR$1,814
- HawkOne$960
- Cardiovascular- Research only$600
- Micra$269
- GENERAL VASCULAR ACCESS$256
- FARXIGA$235
- SelectSecure$169
- HeartMate 3 Left Ventricular Assist Device$136
- Allure Quadra RF CRT Pacemaker$120
- XARELTO$114
- MAMBA$102
How this compares
$20,096 in reported general payments places this provider in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 393 | $423,392 |
| FarxigaDapagliflozin Propanediol | 137 | $134,202 |
| XareltoRivaroxaban | 106 | $130,232 |
| EntrestoSacubitril/Valsartan | 62 | $78,780 |
| BrilintaTicagrelor | 41 | $35,288 |
| JardianceEmpagliflozin | 29 | $32,366 |
| Atorvastatin Calcium | 526 | $8,529 |
| ClopidogrelClopidogrel Bisulfate | 379 | $5,816 |
| Carvedilol | 369 | $3,958 |
| Losartan Potassium | 352 | $3,913 |
| Metoprolol Succinate | 256 | $3,593 |
| Amiodarone Hcl | 185 | $3,549 |
| Amlodipine Besylate | 390 | $3,245 |
| Potassium Chloride | 219 | $3,081 |
| Ranolazine ErRanolazine | 24 | $3,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $310 | $423,392393 claims |
| AstraZenecaFarxiga, Brilinta | $380 | $169,490178 claims |
| Johnson & JohnsonXarelto | $934 | $130,232106 claims |
| NovartisEntresto | $166 | $78,78062 claims |
| Boehringer IngelheimJardiance | $178 | $32,36629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Edmond
- Tiffany MaoEdmond$5K
- Anderson MehrleBartlesville$1.6M
- Eric AuerbachTulsa$636K
- Nicholas HannaTulsa$446K
- Frank GaffneyTulsa$243K
- Stavros StavrakisOklahoma City$174K
- Ravi KodeTulsa$169K
- Gary DykstraBartlesville$122K
- Mark AndersonOklahoma City$113K
- David WilkettTulsa$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.